Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 1 (January)

1. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
   Cancer Res, 66(1): 517-26. [Abstract] [Full-text]
2. Tumor Cell Purging by Ex Vivo Expansion of Hemopoietic Stem Cells from Breast Cancer Patients Combined with Targeting ErbB Receptors.
   Biol Blood Marrow Transplant, 12(1): 68-74. [Abstract] [Full-text]
3. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
   Histopathology, 48(2): 149-56. [Abstract] [Full-text]
4. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
   Mol Immunol, 43(8): 1183-93. [Abstract] [Full-text]
5. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
   Eur J Cancer, 42(2): 186-92. [Abstract] [Full-text]
6. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.
   Breast Cancer Res, 8(1): R4. [Abstract] [Full-text]
7. Biodegradable nanoparticles for direct or two-step tumor immunotargeting.
   Bioconjug Chem, 17(1): 139-45. [Abstract] [Full-text]
8. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer.
   Cancer Res, 66(2): 1025-32. [Abstract] [Full-text]
9. Breast cancer in limited-resource countries: treatment and allocation of resources.
   Breast J, 12: S38-53. [Abstract] [Full-text]
10. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Histopathology, 48(3): 258-67. [Abstract] [Full-text]
11. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
    Br J Cancer, 94(2): 247-52. [Abstract] [Full-text]
12. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
    Br J Cancer, 94(2): 259-67. [Abstract] [Full-text]
13. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
    Int J Gynecol Cancer, 16(1): 416-22. [Abstract] [Full-text]
14. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.
    Expert Rev Anticancer Ther, 6(2): 197-204. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.